Extracorporeal membrane oxygenation may decrease the plasma concentration of remdesivir in a patient with severe coronavirus disease 2019
Remdesivir is an antiviral drug that results in clinical improvement after five days of treatment and accelerates recovery by 31%. No studies have discussed the pharmacokinetic analysis of remdesivir in patients with severe COVID-19 requiring extracorporeal membrane oxygenation (ECMO). A 63-year-old...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/460b8a8db4254010b8c675bebb5d2ae4 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:460b8a8db4254010b8c675bebb5d2ae4 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:460b8a8db4254010b8c675bebb5d2ae42021-11-24T04:30:55ZExtracorporeal membrane oxygenation may decrease the plasma concentration of remdesivir in a patient with severe coronavirus disease 20192214-250910.1016/j.idcr.2021.e01343https://doaj.org/article/460b8a8db4254010b8c675bebb5d2ae42021-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2214250921002997https://doaj.org/toc/2214-2509Remdesivir is an antiviral drug that results in clinical improvement after five days of treatment and accelerates recovery by 31%. No studies have discussed the pharmacokinetic analysis of remdesivir in patients with severe COVID-19 requiring extracorporeal membrane oxygenation (ECMO). A 63-year-old American man who underwent mechanical ventilation and ECMO for severe COVID-19 was administered remdesivir for ten days. The loading dosage was 200 mg at 7 PM on day 12 and 100 mg daily at 0:00 PM from day 13–21, administered within 1 h. The pharmacokinetic analysis was performed. The serum creatinine concentration was within the normal range of 0.5–0.7 mg/dL during treatment. According to the pharmacokinetic analysis, the plasma concentrations of remdesivir and GS-441524 4 h after administration (C4) were 662 ng/mL and 58 ng/mL, respectively, and the concentrations 18 h after administration (C18) were 32 ng/mL and 44 ng/mL, respectively. Therefore, the half-life of remdesivir and GS-441524 was 3.2 and 35.1 h, respectively. Monitoring the plasma concentrations of remdesivir and GS-441524 in patients undergoing ECMO may be necessary.Satoshi IdeSho SaitoTsubasa AkazawaTakahito FuruyaJunichi MasudaMaki NagashimaYusuke AsaiTatsunori OgawaRyohei YamamotoHaruhiko IshiokaKohei KandaAyako OkuhamaYuji WakimotoTetsuya SuzukiYutaro AkiyamaYusuke MiyazatoKeiji NakamuraTakato NakamotoHidetoshi NomotoYuki MoriyamaMasayuki OtaShinichiro MoriokaWataru MatsudaTatsuki UemuraKentaro KobayashiRyo SasakiDaisuke KatagiriSatoshi KutsunaKayoko HayakawaNorio OhmagariElsevierarticleRemdesivirSevere COVID-19Extracorporeal membrane oxygenationPharmacokinetics analysisInfectious and parasitic diseasesRC109-216ENIDCases, Vol 26, Iss , Pp e01343- (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Remdesivir Severe COVID-19 Extracorporeal membrane oxygenation Pharmacokinetics analysis Infectious and parasitic diseases RC109-216 |
| spellingShingle |
Remdesivir Severe COVID-19 Extracorporeal membrane oxygenation Pharmacokinetics analysis Infectious and parasitic diseases RC109-216 Satoshi Ide Sho Saito Tsubasa Akazawa Takahito Furuya Junichi Masuda Maki Nagashima Yusuke Asai Tatsunori Ogawa Ryohei Yamamoto Haruhiko Ishioka Kohei Kanda Ayako Okuhama Yuji Wakimoto Tetsuya Suzuki Yutaro Akiyama Yusuke Miyazato Keiji Nakamura Takato Nakamoto Hidetoshi Nomoto Yuki Moriyama Masayuki Ota Shinichiro Morioka Wataru Matsuda Tatsuki Uemura Kentaro Kobayashi Ryo Sasaki Daisuke Katagiri Satoshi Kutsuna Kayoko Hayakawa Norio Ohmagari Extracorporeal membrane oxygenation may decrease the plasma concentration of remdesivir in a patient with severe coronavirus disease 2019 |
| description |
Remdesivir is an antiviral drug that results in clinical improvement after five days of treatment and accelerates recovery by 31%. No studies have discussed the pharmacokinetic analysis of remdesivir in patients with severe COVID-19 requiring extracorporeal membrane oxygenation (ECMO). A 63-year-old American man who underwent mechanical ventilation and ECMO for severe COVID-19 was administered remdesivir for ten days. The loading dosage was 200 mg at 7 PM on day 12 and 100 mg daily at 0:00 PM from day 13–21, administered within 1 h. The pharmacokinetic analysis was performed. The serum creatinine concentration was within the normal range of 0.5–0.7 mg/dL during treatment. According to the pharmacokinetic analysis, the plasma concentrations of remdesivir and GS-441524 4 h after administration (C4) were 662 ng/mL and 58 ng/mL, respectively, and the concentrations 18 h after administration (C18) were 32 ng/mL and 44 ng/mL, respectively. Therefore, the half-life of remdesivir and GS-441524 was 3.2 and 35.1 h, respectively. Monitoring the plasma concentrations of remdesivir and GS-441524 in patients undergoing ECMO may be necessary. |
| format |
article |
| author |
Satoshi Ide Sho Saito Tsubasa Akazawa Takahito Furuya Junichi Masuda Maki Nagashima Yusuke Asai Tatsunori Ogawa Ryohei Yamamoto Haruhiko Ishioka Kohei Kanda Ayako Okuhama Yuji Wakimoto Tetsuya Suzuki Yutaro Akiyama Yusuke Miyazato Keiji Nakamura Takato Nakamoto Hidetoshi Nomoto Yuki Moriyama Masayuki Ota Shinichiro Morioka Wataru Matsuda Tatsuki Uemura Kentaro Kobayashi Ryo Sasaki Daisuke Katagiri Satoshi Kutsuna Kayoko Hayakawa Norio Ohmagari |
| author_facet |
Satoshi Ide Sho Saito Tsubasa Akazawa Takahito Furuya Junichi Masuda Maki Nagashima Yusuke Asai Tatsunori Ogawa Ryohei Yamamoto Haruhiko Ishioka Kohei Kanda Ayako Okuhama Yuji Wakimoto Tetsuya Suzuki Yutaro Akiyama Yusuke Miyazato Keiji Nakamura Takato Nakamoto Hidetoshi Nomoto Yuki Moriyama Masayuki Ota Shinichiro Morioka Wataru Matsuda Tatsuki Uemura Kentaro Kobayashi Ryo Sasaki Daisuke Katagiri Satoshi Kutsuna Kayoko Hayakawa Norio Ohmagari |
| author_sort |
Satoshi Ide |
| title |
Extracorporeal membrane oxygenation may decrease the plasma concentration of remdesivir in a patient with severe coronavirus disease 2019 |
| title_short |
Extracorporeal membrane oxygenation may decrease the plasma concentration of remdesivir in a patient with severe coronavirus disease 2019 |
| title_full |
Extracorporeal membrane oxygenation may decrease the plasma concentration of remdesivir in a patient with severe coronavirus disease 2019 |
| title_fullStr |
Extracorporeal membrane oxygenation may decrease the plasma concentration of remdesivir in a patient with severe coronavirus disease 2019 |
| title_full_unstemmed |
Extracorporeal membrane oxygenation may decrease the plasma concentration of remdesivir in a patient with severe coronavirus disease 2019 |
| title_sort |
extracorporeal membrane oxygenation may decrease the plasma concentration of remdesivir in a patient with severe coronavirus disease 2019 |
| publisher |
Elsevier |
| publishDate |
2021 |
| url |
https://doaj.org/article/460b8a8db4254010b8c675bebb5d2ae4 |
| work_keys_str_mv |
AT satoshiide extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT shosaito extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT tsubasaakazawa extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT takahitofuruya extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT junichimasuda extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT makinagashima extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT yusukeasai extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT tatsunoriogawa extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT ryoheiyamamoto extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT haruhikoishioka extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT koheikanda extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT ayakookuhama extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT yujiwakimoto extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT tetsuyasuzuki extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT yutaroakiyama extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT yusukemiyazato extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT keijinakamura extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT takatonakamoto extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT hidetoshinomoto extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT yukimoriyama extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT masayukiota extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT shinichiromorioka extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT watarumatsuda extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT tatsukiuemura extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT kentarokobayashi extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT ryosasaki extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT daisukekatagiri extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT satoshikutsuna extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT kayokohayakawa extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 AT norioohmagari extracorporealmembraneoxygenationmaydecreasetheplasmaconcentrationofremdesivirinapatientwithseverecoronavirusdisease2019 |
| _version_ |
1718415972760551424 |